Zeteletinib (BOS-172738; DS-5010) hemiadipate is an orally active, selective RET kinase inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2. Zeteletinib hemiadipate shows exquisite potency for the wild type RET, RETV804M/L gatekeeper mutants, and the most common oncogenic RET mutation M918T. Zeteletinib hemiadipate has potent antitumor activity[1][2][3].
Cerere de ofertă
La cerere
Număr Catalog 804-HY-139590ACategorieAfaceri și industrie > Știință și laboratorFurnizorMedChemExpressGentaurDimensiuneGet quoteTipsingle